Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Eye Infections Market?
The eye infections market has experienced a notable expansion in recent years. The market valuation is predicted to increase from $7.53 billion in 2024 to $7.96 billion in 2025, manifesting a compound annual growth rate (CAGR) of 5.7%. The historical growth is primarily due to greater exposure to environmental pollutants leading to eye irritations, a higher number of eye infection cases among children, a surge in medical tourism for eye surgeries, the preference for combination therapies to address complicated infections, and a rise in allergic conjunctivitis cases.
What Growth Rate Is Forecasted for the Eye Infections Market by 2029?
The market for eye infections is projected to witness robust growth in the upcoming years, escalating to $9.83 billion in 2029 with a compound annual growth rate (CAGR) of 5.4%. Factors contributing to the accelerated growth during the forecast period include an increased incidence of eye infections, a surge in the elderly population susceptible to eye infections, rising diabetes cases affecting eye health, the growing occurrence of contact lens-induced infections, and enhanced understanding of the importance of ocular health. Noteworthy trends during this period include the progression in diagnostic technologies for eye diseases, AI-enabled diagnostic instruments for eye infections, the incorporation of 3D printing technology into ophthalmic treatments, the production of genetically manipulated treatments for rare eye diseases, and the advancement of antibiotics and antiviral agents.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21186&type=smp
Which Key Companies Are Shaping the Future of the Eye Infections Market?
Major companies operating in the eye infections market are Pfizer Inc, F. Hoffmann-La Roche AG, Merck And Co Inc, AbbVie Inc., Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, Essilor International S.A., Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc, Alcon Laboratories Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Carl Zeiss Meditec AG, Santen Pharmaceuticals Co Ltd, Rohto Pharmaceutical Co Ltd, Topcon Corporation, Akorn Pharmaceuticals, Alembic Pharmaceuticals Limited, Novaliq GmbH, Eyevance Pharmaceuticals LLC, Ocular Therapeutix, I-Med Pharma Inc., EyeGate Pharmaceuticals Inc
Which Factors Are Driving Demand in the Eye Infections Industry?
The escalating occurrence and prevalence of disorders related to the eye is anticipated to stimulate the eye infections market. Disorders related to the eye encompass a wide array of conditions including diseases such as cataracts, glaucoma, macular degeneration, and refractive errors like myopia and hyperopia. The swelling number of individuals diagnosed with eye-related disorders can be attributed to various elements including aging populations, modifications in lifestyle, environmental influences, and deficits in diagnostic capabilities resulting in delayed disorder detection. Eye infections aid in the progression or exacerbation of disorders related to the eye by inciting inflammation, initiating tissue damage, and weakening the natural defenses of the eye, eventually leading to the occurrence of complications like vision loss or chronic conditions. For instance, based on data from the World Health Organization, a health authority based in Switzerland, in 2023, 130,746 individuals were surgically treated for advanced trachoma, and 32.9 million received antibiotics, resulting in a global coverage of 29%. Consequently, the escalating occurrence and prevalence of disorders related to the eye is projected to spur the eye infections market onward.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21186&type=smp
How Is the Eye Infections Market Segmented by Several Divisions?
The eye infections market covered in this report is segmented –
1) By Indications: Conjunctivitis, Keratitis, Endophthalmitis, Blepharitis, Stye, Uveitis, Cellulitis, Ocular Herpes
2) By Drug Type: Corticosteroids, Quinolone Antibiotics, Macrolide Antibiotics, Tetracycline Antibiotics, Polyene Antifungals
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Conjunctivitis: Bacterial Conjunctivitis, Viral Conjunctivitis, Allergic Conjunctivitis
2) By Keratitis: Bacterial Keratitis, Viral Keratitis, Fungal Keratitis, Acanthamoeba Keratitis
3) By Endophthalmitis: Post-surgical Endophthalmitis, Post-traumatic Endophthalmitis, Endogenous Endophthalmitis
4) By Blepharitis: Anterior Blepharitis, Posterior Blepharitis
5) By Stye: Internal Stye, External Stye
6) By Uveitis: Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
7) By Cellulitis: Periorbital Cellulitis, Orbital Cellulitis
8) By Ocular Herpes: Herpes Simplex Keratitis, Herpes Simplex Conjunctivitis
What are the Emerging Market Trends Driving the Growth of the Eye Infections Industry?
Leading firms in the eye infections market are prioritizing the development of unique therapies like photodynamic therapy that amplify treatment effectiveness and decrease adverse effects. Photodynamic therapy utilizes a photosensitive medication activated by certain light wavelengths to target and eliminate abnormal or infected cells. Take for example, in December 2024, VisiRose Inc., a U.S. clinical-stage biotech company, established a partnership with Provectus Biopharmaceuticals Inc., a pharmaceutical company, and Bascom Palmer Eye Institute, a health center, both U.S.-based, to introduce Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT). This is a revolutionary, non-invasive research treatment for infectious keratitis and other severe eye infections. RB PDAT is seen as a potential response to the burgeoning worldwide problem of antimicrobial resistance (AMR), providing a comprehensive ocular solution. The therapy aims to be safe, effective, and economical, addressing the pressing need for groundbreaking treatments in this sector.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/eye-infections-global-market-report
Which Regions Are Driving Growth in the Eye Infections Market?
North America was the largest region in the eye infections market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21186
This Report Delivers Insight On:
1. How big is the eye infections market, and how is it changing globally?
2. Who are the major companies in the eye infections market, and how are they performing?
3. What are the key opportunities and risks in the eye infections market right now?
4. Which products or customer segments are growing the most in the eye infections market?
5. What factors are helping or slowing down the growth of the eye infections market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model